OssDsign Catalyst Now Available to U.S. Military Treatment Facilities

OssDsign AB’s nanosynthetic bone graft, OssDsign Catalyst, has been included in the U.S. Department of Defense’s Military Health System’s electronic catalogue (ECAT). This inclusion makes the product universally available through direct order from any of the more than 50 U.S. military treatment facilities.

The uptake of OssDsign Catalyst in ECAT was made possible through a collaboration with Red One Medical, a private-sector scout of medical innovation for the U.S. Department of Veterans Affairs (VA) and the U.S. Department of Defense (DoD). American veterans and military members now have broader access to OssDsign Catalyst.
 
“We are very pleased that OssDsign Catalyst has been included in ECAT making our innovative nanosynthetic bone graft immediately available to all military treatment facilities, independent of individual accounts with specific clinics. By broadening access to this customer group, we take a vital step forward in penetrating the U.S. military market at the same time as we deepen our relationship with Red One Medical, Veterans Affairs, and Department of Defense,” OssDsign CEO Morten Henneveld said.
 
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue. The product was launched in the United States in August 2021 based on preclinical results that surpass those found with other synthetic bone grafts in the most demanding preclinical model for spinal fusion—the Boden model. OssDsign continues to gather clinical evidence with PROPEL, a U.S.-based multi-center prospective spinal fusion registry, and the clinical study TOP FUSION. In September 2023, OssDsign Catalyst further received clearance for use in interbody cages in spinal surgery from the U.S. Food and Drug Administration (FDA), allowing surgeons to use OssDsign Catalyst on-label in any interbody cage cleared for use with synthetic bone grafts. OssDsign Catalyst is the first synthetic bone graft to be cleared to market for interbody use based on bone graft data alone.

“Red One Medical is proud to partner with OssDsign in order to provide innovative medical solutions for America’s military and veteran patients. OssDsign’s product portfolio provides advanced options to treat the specific needs of this patient population” Red One Medical CEO Charles Pollak stated.
 
OssDsign is a Swedish innovator, designer, and manufacturer of personalized bone replacement technology for cranial repair.